These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 27689964)
41. INDOCYANINE GREEN ANGIOGRAPHY OF PACHYCHOROID PIGMENT EPITHELIOPATHY. Ersoz MG; Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M Retina; 2018 Sep; 38(9):1668-1674. PubMed ID: 28723851 [TBL] [Abstract][Full Text] [Related]
42. Variability of subfoveal choroidal thickness measurements in patients with age-related macular degeneration and central serous chorioretinopathy. Kim JH; Kang SW; Kim JR; Kim SJ Eye (Lond); 2013 Jul; 27(7):809-15. PubMed ID: 23598679 [TBL] [Abstract][Full Text] [Related]
43. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749 [TBL] [Abstract][Full Text] [Related]
44. RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHY. Matet A; Daruich A; Zola M; Behar-Cohen F Retina; 2018 Jul; 38(7):1403-1414. PubMed ID: 28570485 [TBL] [Abstract][Full Text] [Related]
45. [Differential diagnostic OCT-criteria of acute and chronic central serous chorioretinopathy]. Doga AV; Klepinina OB; Pedanova EK; Mushkova IA Vestn Oftalmol; 2017; 133(6):10-15. PubMed ID: 29319664 [TBL] [Abstract][Full Text] [Related]
46. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Fung AT; Yannuzzi LA; Freund KB Retina; 2012 Oct; 32(9):1829-37. PubMed ID: 22850219 [TBL] [Abstract][Full Text] [Related]
47. Changes in choroidal thickness after systemic administration of high-dose corticosteroids: a pilot study. Han JM; Hwang JM; Kim JS; Park KH; Woo SJ Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):440-5. PubMed ID: 24370828 [TBL] [Abstract][Full Text] [Related]
48. Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Kim YT; Kang SW; Bai KH Eye (Lond); 2011 Dec; 25(12):1635-40. PubMed ID: 22020172 [TBL] [Abstract][Full Text] [Related]
49. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Quaranta-El Maftouhi M; El Maftouhi A; Eandi CM Am J Ophthalmol; 2015 Sep; 160(3):581-587.e1. PubMed ID: 26133250 [TBL] [Abstract][Full Text] [Related]
50. OCT Angiography Compared to Fluorescein and Indocyanine Green Angiography in Chronic Central Serous Chorioretinopathy. Teussink MM; Breukink MB; van Grinsven MJ; Hoyng CB; Klevering BJ; Boon CJ; de Jong EK; Theelen T Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5229-37. PubMed ID: 26244299 [TBL] [Abstract][Full Text] [Related]
51. Bullous Variant of Central Serous Chorioretinopathy: Expansion of Phenotypic Features Using Multimethod Imaging. Balaratnasingam C; Freund KB; Tan AM; Mrejen S; Hunyor AP; Keegan DJ; Dansingani KK; Dayani PN; Barbazetto IA; Sarraf D; Jampol LM; Yannuzzi LA Ophthalmology; 2016 Jul; 123(7):1541-52. PubMed ID: 27084564 [TBL] [Abstract][Full Text] [Related]
52. CHOROIDAL THICKNESS OF CENTRAL SEROUS CHORIORETINOPATHY SECONDARY TO CORTICOSTEROID USE. Honda S; Miki A; Kusuhara S; Imai H; Nakamura M Retina; 2017 Aug; 37(8):1562-1567. PubMed ID: 27787451 [TBL] [Abstract][Full Text] [Related]
53. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy. An SH; Kwon YH Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1489-1496. PubMed ID: 26553195 [TBL] [Abstract][Full Text] [Related]
55. Identifying central serous chorioretinopathy biomarkers in coexisting diabetic retinopathy: a multimodal imaging study. Dhurandhar DS; Singh SR; Sahoo NK; Goud A; Lupidi M; Chhablani J Br J Ophthalmol; 2020 Jul; 104(7):904-909. PubMed ID: 31563867 [TBL] [Abstract][Full Text] [Related]
56. Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization. Shiragami C; Takasago Y; Osaka R; Kobayashi M; Ono A; Yamashita A; Hirooka K Am J Ophthalmol; 2018 Sep; 193():80-86. PubMed ID: 29940168 [TBL] [Abstract][Full Text] [Related]
57. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967 [TBL] [Abstract][Full Text] [Related]
58. Characteristics of central serous chorioretinopathy complicated by focal choroidal excavation. Suzuki M; Gomi F; Hara C; Sawa M; Nishida K Retina; 2014 Jun; 34(6):1216-22. PubMed ID: 24240563 [TBL] [Abstract][Full Text] [Related]
59. Time-periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. Song IS; Shin YU; Lee BR Am J Ophthalmol; 2012 Aug; 154(2):366-375.e4. PubMed ID: 22633348 [TBL] [Abstract][Full Text] [Related]
60. Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy. Ünlü C; Erdogan G; Gezginaslan TA; Akcay BI; Kardes E; Bozkurt TK Arq Bras Oftalmol; 2016; 79(5):308-311. PubMed ID: 27982209 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]